Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug ...

Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...

Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...

Shares in Novo Nordisk fell as much as 30% after it slashed sales and profits forecasts for the second time this year amid ...

In 2023, sales from Novo Nordisk's GLP-1 diabetes therapies grew 52% year over year. Ozempic and a sibling treatment called Rybelsus are to thank for that growth.

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...